Malignant Primary Gliomas research hub
4 indexed studies · 3 currently recruiting
- recruitingPHASE1, PHASE2
5G-PEARL: Paxalisib in Malignant Brain Tumours
This study, 5G-PEARL, looks at combining two drugs, paxalisib and temozolomide, for people with aggressive brain tumours. It aims to see if this combination is safe and helps shrink tumours. This research could lead to better treatments for these types of cancer.
United Kingdom - recruitingPHASE1
5G-EMERALD: Amivantamab in Malignant Brain Tumours
This study, called 5G-EMERALD, is testing a new drug called amivantamab for people with certain types of aggressive brain tumours. It aims to see if the drug is safe and if it helps shrink tumours, especially in patients whose tumours have a specific genetic feature.
United Kingdom - ongoing, recruitingTherapeutic exploratory (Phase II)
A Multicenter, Open-Label Study with a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients with Recurrent Glioblastoma Multiforme (WHO Grade IV) After Failure of Standard First Line Therapy
This study is testing a new medicine called berubicin for adults with a serious type of brain tumour called glioblastoma, which has come back after standard treatments. We want to see if it helps people live longer and if it's safe.
Spain · France · Italy - recruitingPHASE1, PHASE2
5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours
This study is testing two new drugs, avutometinib and defactinib, alone and with temozolomide, for people with aggressive brain tumours like glioblastoma. It aims to see if they are safe and can shrink tumours, particularly in patients with specific genetic changes.
United Kingdom